Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have earned a consensus recommendation of “Buy” from the seventeen research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and four have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $56.2143.

Several equities research analysts recently commented on the company. Barclays upped their target price on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of Scholar Rock in a report on Tuesday, July 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Canaccord Genuity Group started coverage on Scholar Rock in a report on Monday, April 20th. They set a “buy” rating and a $62.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th.

Scholar Rock Price Performance

SRRK stock opened at $47.29 on Friday. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of -13.17 and a beta of 0.67. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $58.49. The company’s fifty day simple moving average is $50.11 and its 200 day simple moving average is $47.69.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the previous year, the business posted ($0.67) earnings per share. On average, analysts expect that Scholar Rock will post -3.23 earnings per share for the current year.

Insider Activity at Scholar Rock

In other news, Director Katie Peng sold 5,446 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the transaction, the director owned 34,301 shares in the company, valued at approximately $1,848,137.88. This represents a 13.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the transaction, the director directly owned 27,856 shares in the company, valued at $1,500,881.28. This trade represents a 9.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock worth $923,108 over the last ninety days. 10.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after buying an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after acquiring an additional 5,831 shares in the last quarter. Millennium Management LLC lifted its position in Scholar Rock by 37.4% in the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after acquiring an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Scholar Rock by 25.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after acquiring an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new position in Scholar Rock during the 1st quarter valued at about $77,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).